Mumbai: After last week’s pummelling of their shares by the threat of US tariffs, a powerful Indian pharma industry association hit back on issues raised by a section of observers in the US who red-flagged the quality of generic medicines supplied from facilities based in India and China. In its strongest point-wise rebuttal in recent…
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump’s move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines. Reacting to the development, IPA Secretary General Sudarshan Jain said in a statement, “It is not applicable to generics medicines.”…
GENEVA: Generic versions of a groundbreaking injectable HIV-prevention drug will be available for $40 a year in over 100 countries starting in 2027, Unitaid and the Gates Foundation announced Wednesday. The two organizations have signed separate agreements with Indian pharmaceutical companies to produce cheaper generics of lenacapavir – a twice-yearly injection shown to reduce the…
Indian drugmakers Dr Reddy’s Laboratories and Hetero Labs said on Wednesday that they will sell generic versions of a new and highly effective HIV prevention drug for roughly $40 per year beginning in 2027. Lenacapavir, developed by Gilead Sciences and approved earlier this year for HIV prevention under the brand name Yeztugo, is a twice-yearly…
Dr Reddy’s Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets. Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug…
Dr Reddy’s Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the…
Dr Reddy’s Laboratories on Tuesday said it has launched a first-in-class generic medication for chronic constipation in the country. The drug firm has launched Linaclotide, a first-in-class guanylate cyclase-C (GC-C), under the brand name Colozo. Linaclotide is a USFDA-approved medication indicated for adults suffering from chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C)…